Ganetespib for small cell lung cancer

References

• Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.
   PubMed Web of Science ®Google Scholar
• Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011 Dec;32:605–644.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures. Vol. 2015. Atlanta: American Cancer Society; 2015.
   Google Scholar
• Van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011 Nov 12;378:1741–1755.
   PubMed Web of Science ®Google Scholar
• Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rising. Int J Cancer. 2005;117:294–299.
   PubMed Web of Science ®Google Scholar
• Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–271.
   PubMed Web of Science ®Google Scholar
• Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476–484.
   PubMed Web of Science ®Google Scholar
• Arriagada R, Le Chevalier T, Rivière A, et al. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients. Ann Oncol. 2002;13:748–754.
   PubMed Web of Science ®Google Scholar
• Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small cell lung cancer. J Clin Oncol. 1985;3:1471–1477.
   PubMed Web of Science ®Google Scholar
• Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. Japan Clinical Oncology Group. N Engl J Med. 2002;346:85–91.
   PubMed Web of Science ®Google Scholar
• Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–2043.
   PubMed Web of Science ®Google Scholar
• Giaccone G, Ferrati P, Donadio M, et al. Re-induction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol. 1987;23:1697–1699.
   PubMedGoogle Scholar
• Kalemkerian GP, Loo BW, Akerley W, et al. National Comprehensive Cancer Network clinical practice guidelines in oncology, version 2.2017, Small Cell Lung Cancer, NCCN, Inc. 2016.
   Google Scholar
• Fennell DA. Bcl-2 as a target for overcoming chemoresistance in small-cell lung cancer. Clin Lung Cancer. 2003;4:307–313.
   PubMedGoogle Scholar
• Rudin CM, Salgia R, Wang X, et al. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol. 2008;26:870–876.
   PubMed Web of Science ®Google Scholar
• Chiappori AA, Screeder MT, Moezi MM, et al. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Br J Cancer. 2012;106:839–845.
   PubMed Web of Science ®Google Scholar
• Dy GK, Miller AA, Mandrekar SJ, et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol. 2005;16:1811–1816.
   PubMed Web of Science ®Google Scholar
• Horn L, Dahlberg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group study E3501. J Clin Oncol. 2009 Dec 10;27:6006–6011.
   PubMed Web of Science ®Google Scholar
• Pujol JL, Lavole A, Quoix E, et al. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. Ann Oncol. 2015;26:908–914.
   PubMed Web of Science ®Google Scholar
• Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44:1104–1110.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44:1111–1116.
   PubMed Web of Science ®Google Scholar
• Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2:798–811.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:883–895.
   PubMed Web of Science ®Google Scholar
• Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015 Aug 26;7:302.
   Web of Science ®Google Scholar
• Pietanz AMC, Spigel D, Bauer TD, et al. Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). Ejc. 2015;51:S712.
   Google Scholar
• Ying W, Du Z, Sun L, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther. 2012;11:475–484.
   PubMed Web of Science ®Google Scholar
• Proia DA, Foley KP, Korbut T, et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One. 2011;6:e18552.
   PubMed Web of Science ®Google Scholar
• Shimamura T, Perera SA, Foley KP, et al. Ganetespib (STA-9090), a non-geldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res. 2012;18:4973–4985.
   PubMed Web of Science ®Google Scholar
• Ganetespib Investigator’s Brochure. Lexington, MA: Synta Pharmaceuticals. 2015.
   Google Scholar
• Li J, Soroka J, Buchner J. The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones. Biochim Biophys Acta. 2012;1823:624–635.
   PubMed Web of Science ®Google Scholar
• Zhao R, Davey M, Hsu YC, et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the Hsp90 chaperone. Cell. 2005;120:715–727.
   PubMed Web of Science ®Google Scholar
• Sidera K, Patsavoudi E. HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov. 2014 Jan;9:1–20.
   Web of Science ®Google Scholar
• Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther. 2004 Aug;3:1021–1030.
   PubMed Web of Science ®Google Scholar
• Wang Y, Trepel JB, Neckers LM, et al. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs. 2010 Dec;11:1466–1476.
   PubMedGoogle Scholar
• Shimamura T, Lowell AM, Engelman JA, et al. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res. 2005;65:6401–6408.
   PubMed Web of Science ®Google Scholar
• Trepel J, Mollapour M, Giaccone G, et al. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10:537–549.
   PubMed Web of Science ®Google Scholar
• Rodina A, Vilenchik M, Moulick K, et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat Chem Biol. 2007;3:498–507.
   PubMed Web of Science ®Google Scholar
• Shimamura T, Shapiro GI. Heat shock protein inhibition in lung cancer. J Thorac Oncol. 2008 June;3:S152–9.
   PubMed Web of Science ®Google Scholar
• Gogvadze V, Orrenius S, Zhivotovsky B. Multiple pathways of cytochrome c release from mitochondria in apoptosis. Biochim Biophys Acta. 2006 May-Jun;1757:639–647.
   PubMed Web of Science ®Google Scholar
• Zhang R, Luo D, Miao R, et al. Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene. 2005 Jun 2;24:3954–3963.
   PubMed Web of Science ®Google Scholar
• Buchner J. Structure, function and regulation of the Hsp90 machinery. Biomed J. 2013 May-Jun;36:106–117.
   PubMedGoogle Scholar
• Edkins LA. Hsp90 co-chaperones as drug targets in cancer. In: In Mcalpine SR, Edkins LA, eds. Topics in medicinal chemistry. Vol 19, current perspectives heat shock protein inhibitors. Success stories. Switzerland: Springer; 2016. p. 21–51.
   Google Scholar
• Richter K, Moser S, Hagn FJ, et al. Intrinsic inhibition of the Hsp90 ATPase activity. Biol Chem. 2006 Apr 21;281:11301–11311.
   Web of Science ®Google Scholar
• Zuehlke A, Johnson JL. Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers. 2010 Mar;93:211–217.
   PubMed Web of Science ®Google Scholar
• Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem. 2006;75:271–294.
   PubMed Web of Science ®Google Scholar
• Lai CH, Park KS, Lee DH, et al. HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. Oncogene. 2014;33:4867–4876.
   PubMed Web of Science ®Google Scholar
• Lewis J, Devin A, Miller A, et al. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J Biol Chem. 2000;275:10519–10526.
   PubMed Web of Science ®Google Scholar
• Declercq W, Vanden Berghe T, Vandenabeele P. RIP kinases at the crossroads of cell death and survival. Cell. 2009;138:229–232.
   PubMed Web of Science ®Google Scholar
• Gangadharan C, Thoh M, Manna SK. Inhibition of constitutive activity of nuclear transcription factor kappaB sensitizes doxorubicin-resistant cells to apoptosis. J Cell Biochem. 2009;107:203–213.
   PubMed Web of Science ®Google Scholar
• Cho DC, Heath EI, Cleary JM, et al. A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: updated report; general poster session, developmental therapeutics – experimental therapeutics, 2011 ASCO Annual Meeting; Chicago. 2011. Abstract 3051
   Google Scholar
• Goldman JW, Raju RN, Gordon GA, et al. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer. 2013;13:152.
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Goss G, Rosell R, et al. A randomized phase 2 study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small-cell lung cancer. Ann Oncol. 2015;26:1741–1748.
   PubMed Web of Science ®Google Scholar
• Synta pharmaceuticals release summary: Synta announces termination for futility of ganetespib phase 3 GALAXY-2 trial in lung cancer. Lexington, MA:Synta Pharmaceuticals. 2015 Oct.
   Google Scholar
• Leena G. Personal communication. Dana Farber Cancer Institute, 2013.
   Google Scholar
• Subramanian DS, Thompson J, Kramer J et al. A phase Ib/II trial of doxorubicin with ganetespib, a novel Hsp90 inhibitor, in advanced solid tumors, with dose expansion in small cell lung cancer. 16th Annual Meeting of the IASLC, WCLC 2015. Abstract P3.07-003
   Google Scholar
• Lancet JE, Smith BD, Bradley R, et al. A phase 1/2 study of the potent Hsp90 inhibitor STA-9090 administered once weekly in subjects with hematologic malignancies. Blood (ASH Annual Meeting Abstracts). 2010;116:Abstract 3294.
   Web of Science ®Google Scholar
• Padmanabhan S, Kelly K, Heaney M, et al. A phase I study of the potent Hsp90 inhibitor STA-9090 administered twice weekly in subjects with hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 2010;116. Abstract 2898
   Google Scholar
• Matthew Trendowski. PU-H71: an improvement on nature’s solutions to oncogenic Hsp90 addiction. Pharmacological Res. 2015 Sep;99:202–216.
   PubMed Web of Science ®Google Scholar